These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 37401702

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Age-related androgen deficiency and benign prostatic hyperplasia: how to improve the rehabilitation of patients after transurethral surgery?].
    Martov AG, Ergakov DV.
    Urologiia; 2016 Dec; (6):110-117. PubMed ID: 28248054
    [Abstract] [Full Text] [Related]

  • 4. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV, Mete UK, Mandal AK, Singh SK.
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [Abstract] [Full Text] [Related]

  • 5. Prostatic urethral angle might be a predictor of treatment efficacy of α-blockers in men with lower urinary tract symptoms.
    Hou CP, Chen CL, Lin YH, Tsai YL, Chang PL, Juang HH, Tsui KH.
    Drug Des Devel Ther; 2014 Jan; 8():937-43. PubMed ID: 25075177
    [Abstract] [Full Text] [Related]

  • 6. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK.
    Cochrane Database Syst Rev; 2018 Nov 16; 11(11):CD010060. PubMed ID: 30480763
    [Abstract] [Full Text] [Related]

  • 7. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK.
    BJU Int; 2019 Jul 16; 124(1):27-34. PubMed ID: 30681264
    [Abstract] [Full Text] [Related]

  • 8. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.
    BJU Int; 2012 Dec 16; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [Abstract] [Full Text] [Related]

  • 9. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH, Kim Y, Park YW, Lee DG.
    J Sex Med; 2014 May 16; 11(5):1309-15. PubMed ID: 24612680
    [Abstract] [Full Text] [Related]

  • 10. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R.
    BJU Int; 2014 Apr 16; 113(4):623-35. PubMed ID: 24127818
    [Abstract] [Full Text] [Related]

  • 11. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J, Li X, Yang B, Wu C, Fan Y, Li H.
    World J Urol; 2019 Jan 16; 37(1):143-153. PubMed ID: 29948047
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H, Zong H, Cui Y, Li N, Zhang Y.
    J Sex Med; 2014 Jun 16; 11(6):1539-45. PubMed ID: 24621088
    [Abstract] [Full Text] [Related]

  • 13. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
    Salem R, Hairston J, Hohlastos E, Riaz A, Kallini J, Gabr A, Ali R, Jenkins K, Karp J, Desai K, Thornburg B, Casalino D, Miller F, Hofer M, Hamoui N, Mouli S.
    Urology; 2018 Oct 16; 120():205-210. PubMed ID: 30036614
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
    Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero García JM, Fernández-Pro Ledesma A, Cózar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V.
    BJU Int; 2018 Dec 16; 122(6):1049-1065. PubMed ID: 29694707
    [Abstract] [Full Text] [Related]

  • 15. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug 16; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 16. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R, Strand DW, Forbes CM, Case T, Cates JMM, Liu Q, Ramirez-Solano M, Milne GL, Sanchez S, Wang ZY, Bjorling DE, Miller NL, Matusik RJ.
    Prostate; 2021 Sep 16; 81(13):944-955. PubMed ID: 34288015
    [Abstract] [Full Text] [Related]

  • 17. Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.
    Sebastianelli A, Spatafora P, Frizzi J, Saleh O, De Nunzio C, Tubaro A, Vignozzi L, Maggi M, Serni S, McVary KT, Kaplan SA, Gravas S, Chapple C, Gacci M.
    Eur Urol Focus; 2021 Mar 16; 7(2):432-439. PubMed ID: 31606473
    [Abstract] [Full Text] [Related]

  • 18. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function.
    Jung JH, Jae SU, Kam SC, Hyun JS.
    J Sex Med; 2009 Aug 16; 6(8):2299-304. PubMed ID: 19493292
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS.
    J Sex Med; 2017 Aug 16; 14(8):1018-1027. PubMed ID: 28760246
    [Abstract] [Full Text] [Related]

  • 20. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
    Lee JH, Kwon H, Park YW.
    Urology; 2013 Nov 16; 82(5):1008-12. PubMed ID: 24041675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.